Better understanding of ADPKD results in potential new treatment options: ready for the cure?

Esther Meijer*, Paul E. de Jong, Dorien J. Peters, Ronald T. Gansevoort

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary disorders. It accounts for 6% of the incidence of end-stage renal disease in Europe. Over the last decade, knowledge of the pathology underlying this disease has increased rapidly. Attributing important roles to tubular cell ciliary functioning, cell proliferation and fluid secretion, subsequent alterations in levels of intracellular calcium, adenosine 3',5'-cyclic monophosphate (cAMP) and activation of a variety of cellular kinases, including mammalian target of rapamycin (mTOR), has laid out the foundations for development of potentially effective treatments. In this editorial, the possible therapeutic roles for vasopressin antagonists, rapamycin, somatostatin and roscovitine are discussed. Clinical trials have been started to investigate the efficacy and safety of these agents for treating ADPKD in humans.

Original languageEnglish
Pages (from-to)133-138
Number of pages6
JournalJournal of Nephrology
Volume21
Issue number2
Publication statusPublished - 2008

Keywords

  • ADPKD
  • rapamycin
  • roscovitine
  • somatostatin
  • vasopressin receptor antagonist
  • POLYCYSTIC KIDNEY-DISEASE
  • WORSENING HEART-FAILURE
  • VOLUME PROGRESSION
  • BLOOD-PRESSURE
  • MTOR PATHWAY
  • CYCLIC-AMP
  • ANTAGONIST
  • TOLVAPTAN
  • GROWTH
  • TRIAL

Cite this